DekaBank Deutsche Girozentrale cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 10.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 859,360 shares of the medical research company’s stock after selling 103,957 shares during the period. Amgen accounts for 1.3% of DekaBank Deutsche Girozentrale’s portfolio, making the stock its 11th largest position. DekaBank Deutsche Girozentrale’s holdings in Amgen were worth $141,573,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. First Republic Investment Management Inc. increased its stake in shares of Amgen by 3.0% in the fourth quarter. First Republic Investment Management Inc. now owns 558,210 shares of the medical research company’s stock valued at $81,616,000 after buying an additional 16,521 shares during the period. Arbor Wealth Management LLC increased its stake in shares of Amgen by 1.0% in the fourth quarter. Arbor Wealth Management LLC now owns 8,501 shares of the medical research company’s stock valued at $1,424,000 after buying an additional 83 shares during the period. Gratus Capital LLC increased its stake in shares of Amgen by 6.2% in the fourth quarter. Gratus Capital LLC now owns 51,475 shares of the medical research company’s stock valued at $7,526,000 after buying an additional 2,991 shares during the period. Scotia Capital Inc. increased its stake in shares of Amgen by 422.0% in the fourth quarter. Scotia Capital Inc. now owns 39,784 shares of the medical research company’s stock valued at $5,821,000 after buying an additional 32,162 shares during the period. Finally, Tyers Asset Management LLC purchased a new stake in shares of Amgen during the fourth quarter valued at $5,269,000. Institutional investors own 78.80% of the company’s stock.

Shares of Amgen Inc. (NASDAQ AMGN) opened at 177.48 on Wednesday. The stock’s 50 day moving average is $168.06 and its 200-day moving average is $165.18. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The stock has a market cap of $130.52 billion, a PE ratio of 16.86 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.00 by $0.15. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The firm had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the business earned $2.90 earnings per share. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, analysts predict that Amgen Inc. will post $12.46 EPS for the current fiscal year.

WARNING: “DekaBank Deutsche Girozentrale Sells 103,957 Shares of Amgen Inc. (NASDAQ:AMGN)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-sells-103957-shares-of-amgen-inc-nasdaqamgn/1450960.html.

Several brokerages have weighed in on AMGN. Credit Suisse Group set a $177.00 target price on shares of Amgen and gave the company a “hold” rating in a research note on Friday, July 14th. Jefferies Group LLC reiterated a “buy” rating and set a $195.00 price objective on shares of Amgen in a research note on Monday. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research note on Friday, July 14th. ValuEngine upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Leerink Swann reiterated a “market perform” rating and set a $161.00 price objective on shares of Amgen in a research note on Thursday, June 22nd. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and three have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $185.17.

In related news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by company insiders.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.